Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The phase 2b trial compared four doses of temtokibart to placebo in 262 adults with moderate to severe atopic dermatitis, the ...

Qilu Pharmaceutical is paying 280 million Chinese yuan ($38 million) for a licensing and collaboration deal with fellow China ...

Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...

The National Institutes of Health terminated $1.8 billion in grants in fewer than 40 days as part of a whirlwind of cuts ...

Korro Bio is laying off a fifth of its workforce as the Novo Nordisk-partnered biotech funnels resources to its ...

Vor Bio is the latest cell therapy company to reach the end of the road. | Vor Bio is the latest cell therapy company to ...

The FDA has appointed its first chief artificial intelligence officer, with an eye on supporting the agency’s internal IT ...

The Food and Drug Administration is going all in on artificial intelligence. | The Food and Drug Administration is going all ...

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in ...

RallyBio is steering around more tight corners as it announces a further 40% reduction in staffers just weeks after ...